Status:
UNKNOWN
Tdap and Biomarkers of Alzheimer's Disease
Lead Sponsor:
Mindful Diagnostics and Therapeutics, LLC
Collaborating Sponsors:
Infectious Disease Society of America
Conditions:
Alzheimer Disease, Late Onset
Eligibility:
All Genders
50-80 years
Phase:
PHASE1
PHASE2
Brief Summary
Recently, the Tdap (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis) vaccination was added to the list of immunizations associated with lower incidence of dementia. Plasma-based biom...
Detailed Description
A growing number of studies have consistently shown reduced incident risk of dementia associated with a variety of vaccinations. Most recently, data probes of medical claims from two large and dispara...
Eligibility Criteria
Inclusion
- Immuno- competent
- Out of compliance for Tdap vaccine (none within 10 years).
- Ability of give informed consent.
- SAGE test 17 or greater
Exclusion
- Immuno- compromised
- In compliance for Tdap vaccination (within 10 years).
- Known allergy to components of the Tdap vaccine.
- SAGE test \<17
Key Trial Info
Start Date :
May 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 31 2024
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05183516
Start Date
May 1 2023
End Date
March 31 2024
Last Update
August 25 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mindful Diagnostics and Therapeutics
Eau Claire, Wisconsin, United States, 54701-3016